Cecilia Egoavil1, Miriam Juárez1, Carla Guarinos1, María Rodríguez-Soler2, Eva Hernández-Illán1, Cristina Alenda3, Artemio Payá3, Adela Castillejo4, Anna Serradesanferm5, Luis Bujanda6, Fernando Fernández-Bañares7, Joaquín Cubiella8, Luisa de-Castro9, Ana Guerra10, Elena Aguirre11, Alberto Herreros-de-Tejada12, Xavier Bessa13, Maite Herráiz14, José-Carlos Marín-Gabriel15, Judith Balmaña16, Virginia Piñol17, Francisco Rodríguez Moranta18, David Nicolás-Pérez19, Miriam Cuatrecasas20, Francesc Balaguer5, Antoni Castells5, José-Luis Soto4, Pedro Zapater21, Rodrigo Jover22. 1. Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. 2. Service of Digestive Medicine, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. 3. Pathology Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. 4. Molecular Genetics Laboratory, Elche University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. 5. Institut de Malaties Digestives i Metabòliques, CIBERehd, Hospital Clínic, Barcelona, Spain. 6. Gastroenterology Department, Hospital Donostia, Centros de Investigación Biomédica en Red de enfermedades hepáticas y digestivas, Universidad del País Vasco, San Sebastián, Spain. 7. Gastroenterology Department, Hospital Mútua de Terrassa, Terrassa, Spain. 8. Gastroenterology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. 9. Gastroenterology Department, Complexo Hospitalario de Vigo, Vigo, Spain. 10. Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. 11. Oncology Department, Hospital Arnau de Vilanova, Lleida, Spain. 12. Gastroenterology Department, Hospital Puerta de Hierro, Madrid, Spain. 13. Gastroenterology Department, Hospital del Mar Medical Research Institute, Barcelona, Spain. 14. Gastroenterology Department, Clínica Universitaria de Navarra, Pamplona, Spain. 15. Gastroenterology Department, Hospital 12 de Octubre, Madrid, Spain. 16. Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain. 17. Gastroenterology Department, Hospital Universitari Dr. Josep Trueta, Girona, Spain. 18. Gastroenterology Department, Hospital Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. 19. Gastroenterology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. 20. Pathology Department, Hospital Clínic, Barcelona, Spain. 21. Clinical Pharmacology Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. 22. Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain; Service of Digestive Medicine, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain. Electronic address: rodrigojover@gmail.com.
Abstract
BACKGROUND & AIMS: We investigated whether patients with multiple serrated polyps, but not meeting the World Health Organization criteria for serrated polyposis syndrome, and their relatives have similar risks for colorectal cancer (CRC) as those diagnosed with serrated polyposis. METHODS: We collected data from patients with more than 10 colonic polyps, recruited in 2008-2009 from 24 hospitals in Spain for a study of causes of multiple colonic polyps. We analyzed data from 53 patients who met the criteria for serrated polyposis and 145 patients who did not meet these criteria, but who had more than 10 polyps throughout the colon, of which more than 50% were serrated. We calculated age- and sex-adjusted standardized incidence ratios (SIRs) for CRC in both groups, as well as in their first-degree relatives. RESULTS: The prevalence of CRC was similar between patients with confirmed serrated polyposis and multiple serrated polyps (odds ratio, 1.35; 95% confidence interval [CI], 0.64-2.82; P = .40). The SIR for CRC in patients with serrated polyposis (0.51; 95% CI, 0.01-2.82) did not differ significantly from the SIR for CRC in patients with multiple serrated polyps (0.74; 95% CI, 0.20-1.90; P = .70). The SIR for CRC also did not differ significantly between first-degree relatives of these groups (serrated polyposis: 3.28, 95% CI, 2.16-4.77; multiple serrated polyps: 2.79, 95% CI, 2.10-3.63; P = .50). Kaplan-Meier analysis showed no differences in the incidence of CRC between groups during the follow-up period (log-rank, 0.6). CONCLUSIONS: The risk of CRC in patients with multiple serrated polyps who do not meet the criteria for serrated polyposis, and in their first-degree relatives, is similar to that of patients diagnosed with serrated polyposis.
BACKGROUND & AIMS: We investigated whether patients with multiple serrated polyps, but not meeting the World Health Organization criteria for serrated polyposis syndrome, and their relatives have similar risks for colorectal cancer (CRC) as those diagnosed with serrated polyposis. METHODS: We collected data from patients with more than 10 colonic polyps, recruited in 2008-2009 from 24 hospitals in Spain for a study of causes of multiple colonic polyps. We analyzed data from 53 patients who met the criteria for serrated polyposis and 145 patients who did not meet these criteria, but who had more than 10 polyps throughout the colon, of which more than 50% were serrated. We calculated age- and sex-adjusted standardized incidence ratios (SIRs) for CRC in both groups, as well as in their first-degree relatives. RESULTS: The prevalence of CRC was similar between patients with confirmed serrated polyposis and multiple serrated polyps (odds ratio, 1.35; 95% confidence interval [CI], 0.64-2.82; P = .40). The SIR for CRC in patients with serrated polyposis (0.51; 95% CI, 0.01-2.82) did not differ significantly from the SIR for CRC in patients with multiple serrated polyps (0.74; 95% CI, 0.20-1.90; P = .70). The SIR for CRC also did not differ significantly between first-degree relatives of these groups (serrated polyposis: 3.28, 95% CI, 2.16-4.77; multiple serrated polyps: 2.79, 95% CI, 2.10-3.63; P = .50). Kaplan-Meier analysis showed no differences in the incidence of CRC between groups during the follow-up period (log-rank, 0.6). CONCLUSIONS: The risk of CRC in patients with multiple serrated polyps who do not meet the criteria for serrated polyposis, and in their first-degree relatives, is similar to that of patients diagnosed with serrated polyposis.
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Jennifer M Kolb; Christine L Molmenti; Swati G Patel; David A Lieberman; Dennis J Ahnen Journal: Am J Gastroenterol Date: 2020-07 Impact factor: 12.045